Alpha Tau Medical Ltd · NASDAQ:DRTS
Alpha Tau Medical — Investor Presentation (August 2026)
41 slides from Alpha Tau Medical's investor presentation, Aug 10, 2026
Slide 1: Investor Presentation
(NASDAQ:DRTS) Investor Presentation 1
Slide 2: Disclaimer
Disclaimer This presentation (together with oral statements made in connection herewith, the "Presentation") is for informational purposes only to assist interested parties in making their own evaluation with respect to Alpha Tau Medical Ltd. (“Alpha Tau” or the “Company”). The information contained
Slide 3: Alpha Tau Overview
Alpha Tau Overview A novel approach using localized alpha particle radiotherapy designed to precisely destroy solid tumors while sparing surrounding healthy tissue Alpha DaRT Advantages Increasing Corporate Momentum Short-range radiation supporting safety + efficacy Multiple upcoming milestones in n
Slide 4: Anticipated Milestones
Anticipated Milestones Geography Target Indication H2 2026 H1 2027 Data Readout + Recurrent Potential FDA Potential FDA Cutaneous SCC Approval submission Complete Recruitment Initial Readout from Pancreatic Cancer in Pilot Study Pilot Study United States Recurrent Complete Recruitment in Initial Rea
Slide 5: Alpha Radiation is Focal - Short Range Limits Clinical Use
Alpha Radiation is Focal - Short Range Limits Clinical Use Whereas beta and gamma radiation can penetrate tissue with sufficient range to facilitate tumor coverage (while risking damage to healthy tissue), alpha radiation has short range in tissue (<100 μm), which limits its clinical usefulness in l
Slide 6: Alpha DaRT Technology is Designed to Overcome These Limitations
Alpha DaRT Technology is Designed to Overcome These Limitations 224Ra Decay Chain Alpha DaRT leverages the innate decay chain of Radium-224 The decay chain of Radium-224 includes four alpha particles Radium-224 has a half-life of ~3.7 days, while the remaining decay chain has a total half-life of ap
Slide 7: Alpha DaRT - Diffusing Alpha-emitters Radiation Therapy
Alpha DaRT - Diffusing Alpha-emitters Radiation Therapy https://www.youtube.com/watch?v=nwfzJHm0fTQ 7
Slide 8: Therapeutic Focus
Therapeutic Focus We are focused on delivering solutions to three markets that we believe would be best served by the unique characteristics of the Alpha DaRT Localized & Unresectable Metastatic High Unmet Need • Localized tumors that are not • Alpha DaRT being evaluated for • Solid tumors that have
Slide 9: Initial Foray into Superficial Tumors
Initial Foray into Superficial Tumors Alpha DaRT first tested in superficial tumors – tumors of the skin or head & neck, due to: • Ease of access • Straightforward control • Ongoing monitoring • Strong initial preclinical data in Squamous Cell Carcinoma (SCC) Treatment of hundreds of tumors to date:
Slide 10: U.S. Skin Cancer Pilot Study Leading to Pivotal Study
U.S. Skin Cancer Pilot Study Leading to Pivotal Study U.S. Pilot Feasibility Study Locations 5 centers – led by Memorial Sloan Kettering Cancer Center # of Patients 10 Treated Adverse Events 22 reported AE’s, most were mild or moderate No treatment-related serious AEs Pre Treatment Complete Response
Slide 11: Potential cSCC Patient Breakdown - Estimated U.S. Incidence
Potential cSCC Patient Breakdown - Estimated U.S. Incidence 1.8mm new U.S. cSCC incidences per year 1 1 ~419k high-risk cases (~23.3%) 2 2 Targeted population ~64k cases per year Targeted Population Estimated new U.S. cases per year of cSCC with local recurrence and/or nodal metastasis (3.5%)3 1 htt
Slide 12: Tolmar Uro-Oncology Collaboration: Scope
Tolmar Uro-Oncology Collaboration: Scope Indications Covered U.S. Prostate Cancer Market Context #2 1 in 44 Primary: Prostate Cancer (U.S.) Option: Bladder Cancer (U.S.), exercisable upon specified clinical criteria 330,000+ cause of cancer death in men die from prostate new U.S. cases expected this
Slide 13: Tolmar Uro-Oncology Collaboration: Financial Terms
Tolmar Uro-Oncology Collaboration: Financial Terms 1 Payments at Closing — Prostate Cancer (Initial Indication) $20M Equity Investment $15M Manufacturing Investment $35M Total Immediate Proceeds $11.99/share | 25% premium to 30-day VWAP New Alpha DaRT U.S. production facility Equity + Manufacturing
Slide 14: Therapeutic Focus
Therapeutic Focus We are focused on delivering solutions to three markets that we believe would be best served by the unique characteristics of the Alpha DaRT Localized & Unresectable Metastatic High Unmet Need • Localized tumors that are not • Alpha DaRT being evaluated for • Solid tumors that have
Slide 15: Case Study: Potential Systemic Immune Effect Observed in One cSCC Patient
Case Study: Potential Systemic Immune Effect Observed in One cSCC Patient Where a Second, Untreated Lesion Manifested CR Complete Response + Potential Systemic Immune Effect Treated Tumor Untreated Tumors Before After Before After 30-Nov-17 29-Dec-17 30-Nov-17 29-Dec-17 15
Slide 16: Outline of Checkpoint Inhibitor Combination Trial – CTP-HNCPI-00
Outline of Checkpoint Inhibitor Combination Trial – CTP-HNCPI-00 Key Eligibility Criteria Benchmark Comparator Recurrent unresectable or metastatic head and KEYNOTE-048: Benchmark comparator data for 1L Pembrolizumab in patients with recurrent or metastatic HNSCC1 neck squamous cell carcinoma (like
Slide 17: Alpha DaRT + Pembrolizumab in Recurrent / Metastatic HNSCC
Alpha DaRT + Pembrolizumab in Recurrent / Metastatic HNSCC Systemic Response, Survival and Safety - Results (11 Patients Recruited) 100% 44.4% 18.2 mo No Alpha DaRT-Related SAEs Only 2 device-related AEs, both Grade 1 (mild) Systemic Objective Response Rate Systemic Complete Responses Median Overall
Slide 18: Survival and Response vs. the KEYNOTE-048 Benchmark
Survival and Response vs. the KEYNOTE-048 Benchmark Alpha DaRT + Pembrolizumab (n=9) vs. Pembrolizumab Monotherapy, PD-L1 CPS ≥ 1 (n=257) 20.0 20.0 100% 18.2 100 18.0 18.0 90 16.0 16.0 80 14.0 14.0 12.3 70 Percent of patients 12.0 12.0 60 Months Months 10.0 10.0 50 8.0 8.0 40 6.0 6.0 5.4 30 19% 4.0
Slide 19: HNCPI-00-01-003 Pembrolizumab Combination Case Study
HNCPI-00-01-003 Pembrolizumab Combination Case Study 19
Slide 20: Case Background – HNCPI-00-01-003
Case Background – HNCPI-00-01-003 Age 96 Sex Female Tumor Type SCC Date of First Diagnosis Jul-2022 Location Alveolar ridge & lip plus dermal involvement Prior Treatments None Medical Background • Cardio • Dementia • ECOG3 Cancer Stage • Stage IV • T2N1M1 20
Slide 21: Alpha DaRT Treatment
Alpha DaRT Treatment Alpha DaRT After Alpha DaRT Follow-Up Insertion Removal Sept-2022 Oct-2022 Jan-2023 21
Slide 22: Clinical Follow-Up
Clinical Follow-Up Pre-Treatment Nine Weeks Post Treatment 22
Slide 23: Patient Status
Patient Status Patient stopped Pembrolizumab after 12 months Patient still alive with no evidence of disease at October 2024 followup 23
Slide 24: HNSCC Patient Breakdown
HNSCC Patient Breakdown 54,000 cases of HNSCC in US/year¹ 65% are or become R/M HNSCC² ~35,100 cases/year 42% R/M HNSCC patients receive 1L Keytruda treatment³ ~15,000 cases/year ¹Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma Adam Barsouk, John Sukumar Aluru, Pr
Slide 25: Therapeutic Focus
Therapeutic Focus We are focused on delivering solutions to three markets that we believe would be best served by the unique characteristics of the Alpha DaRT Localized & Unresectable Metastatic High Unmet Need • Localized tumors that are not • Alpha DaRT being evaluated for • Solid tumors that have
Slide 26: Focus on Internal Organ Treatments
Focus on Internal Organ Treatments We continue to make progress across internal organ programs, with trials underway in multiple targeted indications and others in various stages of planning and start-up Internal Organs in Focus • Pancreas – clinical trial underway • Liver – clinical trial underway
Slide 27: Pancreatic Cancer
Pancreatic Cancer 27
Slide 28: Alpha DaRT Pancreatic Cancer: Phase I/II Study Results (1/2)
Alpha DaRT Pancreatic Cancer: Phase I/II Study Results (1/2) Demographics and Survival from Trial Enrollment 55 87% 27% No treatment-related deaths Treatment-Associated AEs in 36% subjects; Grade ≥3 in 9% All Grade ≥3 events resolved • 100% feasibility patients fully treated Disease Control Rate Obj
Slide 29: Alpha DaRT Pancreatic Cancer: Phase I/II Study Results (2/2)
Alpha DaRT Pancreatic Cancer: Phase I/II Study Results (2/2) Survival From Prior Line of Chemotherapy Survival from initiation of the prior chemotherapy line is closer to the design of the U.S. IMPACT trial (Alpha DaRT together with 1L chemotherapy) and can facilitate easier comparison to published
Slide 30: IMPACT: U.S. Pancreatic Cancer Pilot Clinical Trial Underway
IMPACT: U.S. Pancreatic Cancer Pilot Clinical Trial Underway N=20 1 Newly Diagnosed Primary Endpoint: Locally Advanced Insertion Incidence of Treatment- Pancreatic Cancer (During Cycles 1-4) Emergent Adverse Events 8-12 cycles of mFOLFIRINOX 2 or Gemcitabine + Abraxane Secondary Endpoints: N=20 Ov
Slide 31: Pancreatic Cancer: Massive and Growing Unmet Need
Pancreatic Cancer: Massive and Growing Unmet Need There are over half a million new cases of pancreatic cancer per year. Approx. 66k of them are in the U.S. Stage 1 Stage 2 Resectable Borderline 13% Resectable 10% Stage 3 Incidence rate of pancreatic Locally cancer is trending upward, Advanced U.S.
Slide 32: Recurrent Glioblastoma (GBM)
Recurrent Glioblastoma (GBM) 32
Slide 33: The Next Frontier: Glioblastoma (GBM) / Brain Cancers
The Next Frontier: Glioblastoma (GBM) / Brain Cancers GBM is one of the most complex, deadly, and treatment-resistant cancers, with estimated average survival of only 8 months¹. There is a high unmet need for a life extending treatment for GBM, with a mortality rate of 93% after 5 years¹ ~14,500 new
Slide 34: REGAIN Clinical Trial Design
REGAIN Clinical Trial Design Primary Endpoints: Treatment Protocol: • One-time treatment with Alpha DaRT Feasibility and Safety using the Alpha radial applicator Recurrent GBM Insertion • The patients will receive steroids to Secondary Endpoints: prevent edema or increase intracranial MRI Response a
Slide 35: Baseline Characteristics of First Three Patients Treated
Baseline Characteristics of First Three Patients Treated Patient 1 Patient 2 Patient 3 Age Recurrent GBM 56 71 56 Sex Male Male Male WHO grade 4 glioma IDH wild Right frontal WHO grade 4 WHO grade 4 glioma IDH wild Initial Diagnosis type, MGMT unmethylated with glioma IDH wild type type, MGMT hyperm
Slide 36: Summary of Interim Results from REGAIN Trial in Recurrent GBM
Summary of Interim Results* from REGAIN Trial in Recurrent GBM • The REGAIN study is a prospective, open-label, single arm, multi-center interventional study designed to evaluate the feasibility and safety of Alpha DaRT seeds for the potential treatment of recurrent glioblastoma • Two of three patie
Slide 37: Therapeutic Focus
Therapeutic Focus We are focused on delivering solutions to three markets that we believe would be best served by the unique characteristics of the Alpha DaRT Localized & Unresectable Metastatic High Unmet Need • Localized tumors that are not • Alpha DaRT being evaluated for • Solid tumors that have
Slide 38: Global Manufacturing Facilities
Global Manufacturing Facilities For efficient commercial operations, we look to establish manufacturing operations in multiple regions of the world, to enable relatively short shipping times to our core markets. We are currently building our first commercial-scale facility in Hudson, NH Jerusalem (O
Slide 39: Anticipated Milestones
Anticipated Milestones Geography Target Indication H2 2026 H1 2027 Data Readout + Recurrent Potential FDA Potential FDA Cutaneous SCC Approval submission Complete Recruitment Initial Readout from Pancreatic Cancer in Pilot Study Pilot Study United States Recurrent Complete Recruitment in Initial Rea
Slide 40: Financial Position
Financial Position Public Since Mar-2022 (NASDAQ:DRTS) $104.8mm in Cash & Deposits at Q2 2026 Well Financed for Execution 40
Slide 41: Saving Lives Globally
AlpheFAU Saving Lives Globally
Alpha Tau Medical — Investor Presentation (August 2026) on 6ix